# US 2024/0002857 A1 · Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002857 A1
- Document ID: US20240002857A1
- Status: Published application
- Kind: A1
- Application number: 18/314,103
- Filed: 2023-05-08
- Published: 2024-01-04
- Earliest claimed: 2022-05-09
- Applicants: Sanegene Bio USA Inc.
- Inventors: Chunyang ZHANG; Zhongfa YANG; Shiyu WANG; Weimin WANG; Chunxue ZHOU; Xiaochuan CAI
- Web page: https://patentgrep.com/patent/US20240002857A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C12Y 101/01062: 17Beta-estradiol 17-dehydrogenase (1.1.1.62)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The disclosure relates to isolated oligonucleotides comprising duplex regions targeting hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), and delivery systems, kits and compositions comprising same, and methods of using same for inhibiting or downregulating HSD17B13.

## Claims

### Claim 1

An isolated oligonucleotide comprising a sense strand and an antisense strand, wherein:
the sense strand comprises a nucleotide sequence that is substantially identical to a region comprising 19-25 nucleotides between any one of the nucleotide positions selected from:
a) 229 to 249;
b) 344 to 364;
c) 474 to 496;
d) 669 to 741;
e) 882 to 947;
f) 999 to 1032;
g) 1101 to 1216;
h) 1297 to 1326; and
i) 1421 to 1507,
from the 5′ end of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA sequence according to SEQ ID NO: 1,
and the antisense strand is substantially complementary to the sense strand such that the sense strand and the antisense strand together form a double stranded region.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The isolated oligonucleotide of claim 1, wherein the sense strand comprises a nucleotide sequence that is substantially identical to a region between any one of the nucleotide positions selected from:
a) 927 to 947;
b) 1007 to 1032;
c) 1194 to 1216; and
d) 1421 to 1445,
from the 5′ end of a HSD17B13 mRNA sequence according to SEQ ID NO: 1.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The isolated oligonucleotide of claim 1, wherein the sense strand comprises a nucleotide sequence that is substantially identical to a region between any one of the nucleotide positions selected from:
a) 344 to 364;
b) 476 to 496;
c) 669 to 741;
d) 882 to 915;
e) 999 to 1030;
f) 1101 to 1121;
g) 1297 to 1326; and
h) 1487 to 1507,
from the 5′ end of a HSD17B13 mRNA sequence according to SEQ ID NO: 1.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The isolated oligonucleotide of claim 1, wherein the sense strand comprises a sequence that is substantially identical to a region comprising the sequence between any one of the nucleotide positions selected from:
a) 229 to 249; and
b) 474 to 494,
from the 5′ end of a HSD17B13 mRNA sequence according to SEQ ID NO: 1.

### Claim at position 8

-12. (canceled)

### Claim 13 (depends on 3)

The isolated oligonucleotide of claim 3, wherein the double stranded region comprises:
i) an antisense strand of nucleic acid sequence according to SEQ ID NO: 2 (5′ UUAUUCAUUUCAUUUUGAUUUU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 31 (5′ AAUCAAAAUGAAAUGAAUAA 3′);
ii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 3 (5′ UAAUGUGAAAUAAAGCUUUGCA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 32 (5′ CAAAGCUUUAUUUCACAUUA 3′);
iii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 4 (5′ UGAAAAAAUGUGAAAUAAAGCU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 33 (5′ CUUUAUUUCACAUUUUUUCA 3′);
iv) an antisense strand of nucleic acid sequence according to SEQ ID NO: 5 (5′ UAUCUUAAAGAAAACCUUUUAA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 34 (5′ AAAAGGUUUUCUUUAAGAUA 3′);
v) an antisense strand of nucleic acid sequence according to SEQ ID NO: 6 (5′ UAUAUCUUAAAGAAAACCUUUU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 35 (5′ AAGGUUUUCUUUAAGAUAUA 3′);
vi) an antisense strand of nucleic acid sequence according to SEQ ID NO: 7 (5′ UUUUCAAAUGCUGAAUCUUAAA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 36 (5′ UAAGAUUCAGCAUUUGAAAA 3′);
vii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 8 (5′ UAUCUUUCAAAUGCUGAAUCUU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 37 (5′ GAUUCAGCAUUUGAAAGAUA 3′); or
viii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 9 (5′ UAAUCUUUCAAAUGCUGAAUCU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 38 (5′ AUUCAGCAUUUGAAAGAUUA 3′).

### Claim 14 (depends on 5)

The isolated oligonucleotide of claim 5, wherein the double stranded region comprises:
i) an antisense strand of nucleic acid sequence according to SEQ ID NO: 10 (5′ UUUCACCUGAUUUAGAGAGCGA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 39 (5′ GCUCUCUAAAUCAGGUGAAA 3′);
ii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 11 (5′ UGUGAUCCAAAAAUGUCCUAGG 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 40 (5′ UAGGACAUUUUUGGAUCACA 3′);
iii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 12 (5′ UGAGACAUGAGGUUUUGAUACC 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 41 (5′ UAUCAAAACCUCAUGUCUCA 3′);
iv) an antisense strand of nucleic acid sequence according to SEQ ID NO: 13 (5′ UAUAAUCUUGUGCUUGGAUUUU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 42 (5′ AAUCCAAGCACAAGAUUAUA 3′);
v) an antisense strand of nucleic acid sequence according to SEQ ID NO: 14 (5′ UAAUAUUCUGCAUACGAUUUAA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 43 (5′ AAAUCGUAUGCAGAAUAUUA 3′);
vi) an antisense strand of nucleic acid sequence according to SEQ ID NO: 15 (5′ UAAAUUGAAUAUUCUGCAUACG 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 44 (5′ UAUGCAGAAUAUUCAAUUUA 3′);
vii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 16 (5′ UUUCAAAUUGAAUAUUCUGCAU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 45 (5′ GCAGAAUAUUCAAUUUGAAA 3′);
viii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 17 (5′ UCUGCUUCAAAUUGAAUAUUCU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 46 (5′ AAUAUUCAAUUUGAAGCAGA 3′);
ix) an antisense strand of nucleic acid sequence according to SEQ ID NO: 18 (5′ UAUAAAGCUUUGCAGCAUUGAU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 47 (5′ CAAUGCUGCAAAGCUUUAUA 3′);
x) an antisense strand of nucleic acid sequence according to SEQ ID NO: 19 (5′ UAAUAAAGCUUUGCAGCAUUGA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 48 (5′ AAUGCUGCAAAGCUUUAUUA 3′);
xi) an antisense strand of nucleic acid sequence according to SEQ ID NO: 20 (5′ UGUGAAAUAAAGCUUUGCAGCA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 49 (5′ CUGCAAAGCUUUAUUUCACA 3′);
xii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 21 (5′ UAAAUGUGAAAUAAAGCUUUGC 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 50 (5′ AAAGCUUUAUUUCACAUUUA 3′);
xiii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 22 (5′ UAAAAUGUGAAAUAAAGCUUUG3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 51 (5′ AAGCUUUAUUUCACAUUUUA 3′);
xiv) an antisense strand of nucleic acid sequence according to SEQ ID NO: 23 (5′ UAAAAAUGUGAAAUAAAGCUUU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 52 (5′ AGCUUUAUUUCACAUUUUUA 3′);
xv) an antisense strand of nucleic acid sequence according to SEQ ID NO: 24 (5′ UUAUUCUUGAGAAACAGGAAGA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 53 (5′ UUCCUGUUUCUCAAGAAUAA 3′);
xvi) an antisense strand of nucleic acid sequence according to SEQ ID NO: 25 (5′ UAUGCUACUUGAACAGUCUUAA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 54 (5′ AAGACUGUUCAAGUAGCAUA 3′);
xviii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 26 (5′ UUUGGAAUGCUACUUGAACAGU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 55 (5′ UGUUCAAGUAGCAUUCCAAA3′);
xix) an antisense strand of nucleic acid sequence according to SEQ ID NO: 27 (5′ UCAGAUUGGAAUGCUACUUGAA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 56 (5′ CAAGUAGCAUUCCAAUCUGA 3′); or
xx) an antisense strand of nucleic acid sequence according to SEQ ID NO: 28 (5′ UGUAAUAAAGUCCAGAAUAGAG 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 57 (5′ CUAUUCUGGACUUUAUUACA 3′).

### Claim 15 (depends on 7)

The isolated oligonucleotide of claim 7, wherein the double stranded region comprises:
i) an antisense strand of nucleic acid sequence according to SEQ ID NO: 29 (5′ UUAUUAAUAUCCCACAGAACCA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 58 (5′ GUUCUGUGGGAUAUUAAUAA 3′);
ii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 30 (5′ UGAUCCAAAAAUGUCCUAGGAU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 59 (5′ CCUAGGACAUUUUUGGAUCA 3′); or
iii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 30 (5′ UGAUCCAAAAAUGUCCUAGGAU 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO:60 (5′ CCUAGGACAUUUUUGIAUCA 3′).

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The isolated oligonucleotide of claim 1, wherein the sense strand comprises a nucleotide sequence that is identical to a region between any one of the nucleotide positions selected from:
a) 229 to 249;
b) 669 to 689; and
c) 1007 to 1027,
from the 5′ end of a HSD17B13 mRNA sequence according to SEQ ID NO: 1.

### Claim 18 (depends on 17)

The isolated oligonucleotide of claim 17, wherein the antisense strand comprises a nucleotide sequence according to any one of: SEQ ID NOs: 3, 12 and 29.

### Claim 19 (depends on 17)

The isolated oligonucleotide of claim 17, wherein the sense strand comprises a nucleotide sequence according to any one of: SEQ ID NOs: 32, 41 and 58.

### Claim 20 (depends on 17)

The isolated oligonucleotide of claim 17, wherein the double stranded region comprises an antisense strand of nucleic acid sequence according to SEQ ID NO: 3 (5′ UAAUGUGAAAUAAAGCUUUGCA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 32 (5′ CAAAGCUUUAUUUCACAUUA 3′).

### Claim 21 (depends on 17)

The isolated oligonucleotide of claim 17, wherein the double stranded region comprises an antisense strand of nucleic acid sequence according to SEQ ID NO: 12 (5′ UGAGACAUGAGGUUUUGAUACC 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 41 (5′ UAUCAAAACCUCAUGUCUCA 3′).

### Claim 22 (depends on 17)

The isolated oligonucleotide of claim 17, wherein the double stranded region comprises an antisense strand of nucleic acid sequence according to SEQ ID NO: 29 (5′ UUAUUAAUAUCCCACAGAACCA 3′), and a sense strand of nucleic acid sequence according to SEQ ID NO: 58 (5′ GUUCUGUGGGAUAUUAAUAA 3′).

### Claim at position 19

-26. (canceled)

### Claim 27 (depends on 1)

The isolated oligonucleotide of claim 1, wherein the antisense strand comprises nucleotides modified with 2′-F modification (“F”), and nucleotides modified with 2′-O-methyl modification (“M”), according to the formula:
3′(M)0(F)0(M)6(F)1(M)1(F)1(M)3(F)1(M)2(F)1(M)1(F)1(M)1(F)2(M)15′.

### Claim 28 (depends on 1)

The isolated oligonucleotide of claim 1, wherein the sense strand comprises nucleotides modified with 2′-F modification (“F”), and nucleotides modified with 2′-O-methyl modification (“M”), according to the formula:
5′(M)0(F)0(M)5(F)1(M)1(F)4(M)93′.

### Claim 29 (depends on 1)

The isolated oligonucleotide of claim 1, wherein the antisense strand comprises any one of:
i) an antisense strand of nucleic acid sequence according to SEQ ID NO: 440 (5′ [McEPmUs][fAs][fA][mU][fG][mU][f 1][mA][mA][fA][mU][mA][mA][fA][mG][fC][mU][mU][mU][mGs][mCs][mA] 3′);
ii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 442 (5′ [McEPmUs][fGs][fA][mG][fA][mC][fA][mU][mG][fA][mG][mG][mU][fU][mU][fU][mG][mA][mU][mAs][mCs][mC] 3′); or
iii) an antisense strand of nucleic acid sequence according to SEQ ID NO: 444 (5′ [McEPmUs][fUs][fA][mU][fU][mA][fA][mU][mA][fU][mC][mC][mC][fA][mC][fA][mG][mA][mA][mCs][mCs][mA] 3′),
wherein “m” is a 2′-O-methyl modified nucleotide, “f” is a 2′-F modified nucleotide, “s” is a phosphorothioate internucleotide linkage, “MeEP” is a mono methyl protected phosphate mimic.

### Claim 30 (depends on 1)

The isolated oligonucleotide of claim 1, wherein the sense strand comprises any one of:
i) a sense strand of nucleic acid sequence according to SEQ ID NO: 441 (5′ [mCs][mAs][mA][mA][mG][fC][mU][fU][fU][fA][fU][mU][mU][mC][mA][mC][mA][mUs][m Us][mA][G1b][G1b][G1b] 3′);
ii) a sense strand of nucleic acid sequence according to SEQ ID NO: 443 (5′ [mUs][mAs][mU][mC][mA][fA][mA][fA][fC][fC][fU][mC][mA][mU][mG][mU][mC][mUs][m Cs][mA][G1b][G1b][G1b] 3′); or
iii) a sense strand of nucleic acid sequence according to SEQ ID NO: 445 (5′ [mGs][mUs][mU][mC][mU][fG][mU][fG][fG][fG][fA][mU][mA][mU][mU][mA][mA][mUs][m As][mA][G1b][G1b][G1b] 3′),
wherein “m” is a 2′-O-methyl modified nucleotide, “f” is a 2′-F modified nucleotide, “s” is a phosphorothioate internucleotide linkage, and “G1b” is a GalNac G1b moiety.

### Claim 31 (depends on 1)

A vector encoding the isolated oligonucleotide of claim 1.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

A pharmaceutical composition comprising the isolated oligonucleotide of claim 1, and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 34

(canceled)

### Claim 35 (depends on 1)

A method of inhibiting or downregulating the expression or level of HSD17B13, or treating or preventing a disease or disorder associated with aberrant or increased expression or activity of HSD17B13 or a disease or disorder where HSD17B13 plays a role, in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of the isolated oligonucleotide of claim 1.

### Claim 36

(canceled)
